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Mesenchymal stem cells (MSCs) are ideal for cell-based
therapy in various inflammatory diseases because of
their immunosuppressive and tissue repair properties.
Moreover, their immunosuppressive properties and low
immunogenicity contribute to a reduced or weakened
immune response elicited by the implantation of
allogeneic MSCs compared with other cell types.
Therefore, implantation of allogeneic MSCs may be a
promising cell-based therapy. In this review, we first
summarize the unique advantages of allogeneic MSCs
for therapeutic applications. Second, we critically
analyze the factors influencing their therapeutic effects,
including administration routes, detection time-points,
disease models, differentiation of MSCs in vivo, and
timing and dosage of MSC administration. Finally,
current approaches to allogeneic MSC application are
discussed. In conclusion, allogeneic MSCs are a
promising option because of their low immunogenicity
and immunosuppressive and tissue repair capabilities.
Further investigations are needed to enhance the
consistency and efficacy of MSCs when used as a
cell-based therapy in inflammatory diseases as well as
for tissue repair.potential limitations. First, it is difficult to obtain sufficient
auto-MSCs from some patients—for example, ASCs fromIntroduction
Mesenchymal stem cells (MSCs) are classified into
various groups according to the cell source, such as
bone marrow-derived MSCs (BM-MSCs), adipose-derived
MSCs (ASCs), and umbilical cord MSCs. These MSC
types share common features, which have been described
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main plastic-adherent under standard culture conditions;
(b) express CD105, CD73, and CD90 and fail to express
CD45, CD34, CD14 or CD11b, CD79a or CD19, and
major histocompatibility complex (MHC) class II mole-
cules; and (c) differentiate into osteoblasts, adipocytes,
and chondrocytes in vitro [1].
The following unique properties appear to make MSCs
ideal for cell-based therapy in various diseases. First,
they have multilineage potential, differentiating into vari-
ous cell types, including adipocytes, hepatocytes, and
neurocytes [2–4]. This makes them useful as seed cells
to replace damaged tissue in tissue engineering applica-
tions. Second, they alleviate tissue injury and promote
tissue repair by their anti-apoptotic and cytoprotective
effects and angiogenic capacity [5, 6]. Third, they have
become a promising approach to treat graft-versus-host
disease (GVHD) and autoimmune disease because of
their immunomodulatory properties and low immuno-
genicity [7–9].Advantages of allogeneic MSCs for therapeutic
applications
Autologous MSC (auto-MSC) applications have some
thinner patients or BM-MSCs from myelofibrosis patients.
Second, MSCs isolated from elderly donors have de-
creased biological activity, including differentiation and
regenerative potential [10, 11], resulting in disappointing
treatment outcomes. Third, some systemic diseases, such
as diabetes [12], rheumatoid arthritis [13], and systemic
lupus erythematosus (SLE) [14], alter the intrinsic proper-
ties of MSCs, thus impairing their protective function. It
is difficult to obtain sufficient quantities of healthy auto-
MSCs with high activity from patients with these diseases.
MSC implantation in these patients is therefore challen-
ging. Obtaining allogeneic MSCs (allo-MSCs) from youngis distributed under the terms of the Creative Commons Attribution 4.0
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issue.
Furthermore, auto-MSC extraction is time-consuming,
making it difficult to use them promptly to treat acute
diseases such as stroke and myocardial infarction. In
contrast, allo-MSCs are readily available and can be
administered immediately. In addition, commercial allo-
MSC production should guarantee quality control and
reduce the cost of cell therapies. Therefore, allo-MSCs
are promising alternatives to auto-MSCs, with advan-
tages with regard to time, cost, and quality assurance.
Above all, the immunosuppressive properties and low
immunogenicity of allo-MSCs contribute to a reduced
immune response after implantation. The following mech-
anisms are responsible for their immunosuppression and
low immunogenicity. First, their expression of a low or
modest level of MHC class I molecules and lack of expres-
sion of MHC class II and co-stimulatory molecules, such
as CD40, CD80 (B7-1), and CD86 (B7-2), leads to low
immunogenicity, thus avoiding immune responses in
recipients [15]. Second, MSCs inhibit the activity of vari-
ous immune cells, including T cells, B cells, natural killer
cells, and dendritic cells via cell–cell contacts and soluble
factors [16, 17].
Factors influencing the protective effect of
allo-MSCs
The concept that allo-MSCs may have equivalent effi-
cacy to auto-MSCs has become well established. Increas-
ingly, however, in vivo studies report that allo-MSCs are
not fully immune privileged and probably cause an
immune response despite the immunosuppressive proper-
ties and low immunogenicity of MSCs being documented
both in vivo and in vitro. Currently, different research
groups have obtained inconsistent or even contradictory
results on the therapeutic effects of allo-MSCs in various
studies [18–21]. Therefore, the in vivo immunogenicity of
allo-MSCs and the relationship between immunogenicity
and their protective effects remains to be determined. In
addition, the cause of the inconsistent results has yet to be
established. We describe in detail the factors that influ-
ence the therapeutic effects of allo-MSCs below.
Administration routes versus therapeutic effects
The routes of MSC administration are classified into
two categories: systemic and topical. Some studies have
reported that the administration route of allo-MSCs
determines the extent of their protective effects.
There are two types of topical administration: intrale-
sional injection (e.g., intracranial, intracerebral, subcuta-
neous) and local vascular injection (e.g., superior vena
cava, mesenteric blood vessels, coronary artery). Com-
pared with systemic administration, topical administra-
tion routes may have a common advantage in that MSCsarrive directly at the target tissue with little loss during
migration [18, 22]. It was demonstrated that allo-MSCs
loaded onto cancellous bone granules have a similar
efficacy to auto-MSCs for bone regeneration in bone
defect models [23]. Acar et al. [24] reported that direct
injection of allo-MSCs into marrow cavities (i.e., intra-
bone marrow delivery) had similar effects to intravenous
(IV) injection in irradiation-damaged bone marrow re-
pair. However, Gu et al. [25] reported that allo-MSCs
implanted via the intrapancreatic route had a greater
effect on hyperglycemia correction and increasing insu-
lin secretion in the serum of diabetic rats than those
administered via the IV route.
Types of systemic administration include IV, intra-
arterial, and intraperitoneal injection. IV is the most com-
mon method in preclinical and clinical settings because of
its convenience. However, MSCs administered via this
route are more easily trapped in small lung capillaries
because of their larger size and expression of cell adhesion
molecules [26, 27]. Lung entrapment of MSCs decreases
the number of MSCs delivered to target tissues and can
result in ineffectual treatment [28]. However, some reports
have shown that auto-MSCs delivered via IV injection
have protective effects in various animal models even
when lung entrapment occurs [3, 29]. Similar to auto-
MSCs, IV administration of allo-MSCs improved islet
function and corrected hyperglycemia without immune
rejection in a diabetic rat model [25]. In a rat ischemic
stroke model, allogeneic ASCs and BM-MSCs delivered
via IV injection decreased cell death, increased cellular
proliferation, and improved the functional recovery of the
brain [3].
Administration routes determine the microenviron-
ments that MSCs first encounter after entering the
patient’s body, thus influencing their differentiation,
immunogenicity, and survival [30]. However, the mecha-
nisms responsible for these effects are far from clear
because of the limited number of studies performed, and
it is necessary to investigate which administration routes
of MSCs are best for the diverse range of disease models.
Evaluation time-points versus therapeutic effects
Short-term (i.e., within a month) but not long-term pro-
tection has usually been evaluated in most studies that
demonstrate the protective effects of MSCs [29, 31]. In
contrast, most studies evaluating their long-term effect
have shown no or limited protection [32, 33]. Therefore,
the different time-points used in these investigations
probably contribute to their different conclusions on the
protective effects of MSCs. As MSCs have low immuno-
genicity but are not fully immune privileged in vivo,
immune rejection of allo-MSCs is induced. However,
this is too weak to eliminate them immediately, so allo-
MSCs can survive for a short period after transplantation.
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pressive function in the short-term but are less effective in
the long-term. More studies into implanted MSCs are
urgently needed to simultaneously evaluate their short-
and long-term protective effects.
Disease models versus therapeutic effects
It is well established that allo-MSCs can alleviate GVHD
in the setting of allogeneic hematopoietic stem cell trans-
plantation in preclinical [34] and clinical studies [35].
Moreover, the Prochymal brand of remestemcel-L, the
first stem cell drug, has been approved for the market.
Prochymal is a MSC product prepared from bone marrow
aspirates of healthy human donors, and shows potential
for treating acute GVHD [19, 36]. In addition to GVHD
models, the efficacy and safety of allo-MSCs have been
widely documented in autoimmune disease models. Allo-
MSCs can reduce the clinical relapse rate and improve the
function of damaged organs in models of autoimmune
diseases, including SLE and Crohn's disease [9, 37]. The
technology available for allo-MSC applications for GVHD
and Crohn's disease is currently comparatively mature; of
the 13 available clinical trials on Prochymal registered in
clinical trials databases, five have been for use in GVHD
and Crohn's disease.
Although MSCs display a protective function in GVHD
and autoimmune disease models, controversy exists about
allo-MSC immunosuppression in the setting of solid
organ transplantation [20, 38, 39]. For example, allo-
MSCs show no graft protection in many studies [20].
Unexpectedly, some studies have reported that allo-MSCs
are ineffective at prolonging allograft survival and tend to
cause more rapid—and a greater degree of—immune
rejection [20, 21]. Therefore, the use of various disease
models may be one reason for the controversy about the
protective effects of allo-MSCs.
Differentiation of MSCs in vivo versus therapeutic effects
The low immunogenicity of MSCs does not ensure they
are fully immune privileged in an in vivo setting. Allo-
MSC immunogenicity after differentiation can weaken
or even inhibit their therapeutic effects. Huang et al.
[33] reported that expression of immunogenic MHC-Ia
and MHC-II is strongly increased in differentiated MSCs
compared with undifferentiated MSCs in a rat myocar-
dial infarction model. The implanted allo-MSCs induced
expression of a specific anti-donor alloantibody in serum
after differentiation (5 weeks), which limited the long-
term (more than 5 months) protective effects of MSCs
on the heart. However, allo-MSCs were as effective as
auto-MSCs in improving cardiac function for at least
3 months. In a diabetic rat model, Gu et al. [25] reported
that implanted allo-MSCs did not express MHC-II and
did not trigger cellular cytotoxicity and immune rejectionuntil they differentiated into insulin-producing cells. Even
so, the therapeutic effects of allo-MSCs for damaged
pancreas were maintained after their differentiation.
From these results, we find that the presence of
immunogenicity after differentiation decreases the thera-
peutic effects of allo-MSCs, although it does not indicate
the definite loss of protective effects immediately, which is
consistent with previous reports [40, 41]. We speculate on
the probable reasons for this. First, even in specific induc-
tion conditions in vitro, only some MSCs differentiate;
therefore, sufficient allo-MSCs remain in an undifferenti-
ated state to ensure their survival and execute their
protective effects on the immune systems of recipients.
Second, the immunoreaction is too weak to quickly
eliminate differentiated MSCs; a recipient’s immune sys-
tems needs some time to eliminate all of the allo-MSCs.
Current data on this issue are lacking and the specific
protective mechanism that functions after differentiation
needs to be further investigated.
Timing of MSC administration versus therapeutic effect
The immune status of a recipient before and after allo-
graft organ transplantation determines the survival of
implanted allo-MSCs. Crop et al. [42] reported that,
before kidney transplantation, recipient peripheral blood
mononuclear cells (PBMCs) did not lyse allo-MSCs, but
that PBMCs isolated 3, 6, and 12 months after trans-
plantation showed increasing ability to lyse allo-MSCs.
In vivo experiments have shown that the different timing
of auto-MSC transplantation determines their therapeutic
effect in a myocardial infarction model [43]. As reported
for auto-MSCs, a recent study by Rigol et al. [41] showed
that allo-ASCs induce better neovascularization and a
better long-term prognosis at 15 min after reperfusion
than a week later. In addition, Cho et al. [44] reported that
a single injection of MSCs, either systemically or subcuta-
neously, did not induce a detectable adaptive immune
response. However, repeated injection of MSCs into the
same site resulted in alloantibody production. Therefore,
differences in administration timing have probably led to
inconsistent conclusions regarding the immunogenicity
and therapeutic effects of allo-MSCs.
Dosage of MSC administration versus therapeutic effects
Different doses of MSCs have different immune response
or protective effects. Allo-MSCs injected intracranially in-
duced transient dose-dependent immune rejection, which
reduced MSC engraftment levels and their protective
effects [45, 46]. In contrast, an animal study on myocardial
infarction by Wolf et al. [47] indicated that allo-MSCs lim-
ited myocardial infarct size and improved the functional
outcome in a dose-dependent manner. Currently, the
relationship between MSC dose and therapeutic effects is
far from clear. Therefore, the optimal dose of implanted
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their therapeutic function in various disease models.
Application strategies for allogeneic MSCs
Many unique features make MSCs a promising thera-
peutic option in tissue repair and immunosuppression.
Although the direct application of allo-MSCs has a cer-
tain protective effect, various measures taken during or
before transplantation can have a great effect on improv-
ing treatment outcomes (Table 1).
Combined application with immunosuppressants
The co-application of MSCs with immunosuppressants
increases their protective effects compared with theirTable 1 Strategies to enhance efficiency of MSC-based treatment
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graftment by suppressing the immune response to allo-
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The effectiveness of genetically modified auto-MSCs
has been reported in different disease models [50–52].
Similarly, the protective effect of allo-MSCs was im-
proved by gene modification. de la Garza-Rodea et al.
[53] observed that BM-MSCs with a modified US11 gene
led to decreasing expression of MHC-1. The US11 gene
modification contributed to evasion of recognition by
cytotoxic lymphocytes and extended the persistence of
MSCs in the allogeneic host. In contrast to wild-type allo-
MSCs, allo-MSCs expressing cytotoxic T lymphocyte
associated antigen-4 (CTLA4Ig) demonstrated enhanced
inhibition of T-cell responses [54]. The genetically modi-
fied MSCs delayed the onset of inflammatory arthritis and
decreased the amount of damage in collagen-induced
arthritis. Chen et al. [55] reported that MSCs expressing
allogeneic C-X-C chemokine receptor type 4 (CXCR-4)
promoted a greater level of hematopoietic recovery
and sustained hematopoiesis compared with unmodi-
fied MSCs. The protection of MSCs resulted from the
enhanced ability to home to bone marrow and spleen.
Allo-MSCs with modified Epo gene significantly in-
creased protective effects for kidney and improved the
survival of mice in an acute kidney injury model [56].
Method of cell engineering
The fate of implanted allo-MSCs is tightly influenced by
the microenvironment encountered. Intracellular depots
have been generated through cell engineering to provide
controlled microenvironments for MSCs. These depots
continuously release drugs and cellular factors which
affect the homing, viability, differentiation of MSCs, etc.
For example, MSCs engineered with poly lactide-co-
glycolic acid particles containing dexamethasone pro-
moted the osteogenic differentiation of MSCs [57].
Hydrogels were previously reported to be promising
allo-MSC carriers for tissue engineering. Dhingra
et al. [58] reported that the use of a biodegradable,
temperature-sensitive hydrogel for the slow release of
prostaglandin E2 at the cell implantation site could
prevent rejection of implanted allo-MSCs and restore
cardiac function in a myocardial infarction model.
Interestingly, hydrogels themselves have been docu-
mented to modulate the immunological properties of
allo-MSC tissue-engineered cartilage. Neonatal rabbit
allo-MSCs induced lower allogeneic lymphocyte pro-
liferation and reduced the expression of MHC class I
and II molecules when seeded in a collagen hydrogel
compared with sponge and membrane [59].
Recently, there have been fewer studies on applications
of allo-MSCs compared with auto-MSCs. Auto-MSC
studies have provided insight into allo-MSC applications.
For example, the pre-stimulation of auto-MSCs with
interferon-gamma increased their immunosuppressivecapacity, reduced mucosal damage, and enhanced their
therapeutic efficacy in animal models of colitis [60]. In
addition, hypoxia preconditioning is reported to increase
the protective effect of auto-MSCs in disease models
such as hemorrhagic stroke [61], ischemia [62], and pul-
monary fibrosis [63].
Conclusion and future perspectives
MSCs have shown promise in cell replacement or trans-
plantation for their immunosuppressive and tissue repair
effects. However, it is difficult to isolate sufficient quan-
tities of healthy auto-MSCs with high activity from older
or thinner people and patients with diabetes, rheumatoid
arthritis or SLE. Moreover, auto-MSCs are not suited to
the prompt treatment of acute diseases because extraction
of them is time-consuming. Because of their immune sup-
pression properties and low immunogenicity compared
with other cell types, the implantation of allo-MSCs may,
therefore, be more reasonable and appropriate. Although
various studies have provided inconsistent conclusions on
the therapeutic effects of allo-MSCs, allo-MSCs are still a
promising option in immunosuppressive and tissue repair
therapy.
To date, we have been unable to obtain consistent re-
sults from the insufficient pre-clinical and clinical data on
the immunogenicity and protective effects of allo-MSCs.
The following issues need to be addressed in further
research. First, which immune molecules and cells are
involved in the potential immune response? Second, what
is the dynamic fate of implanted allogeneic ASCs, includ-
ing being eliminated by recipients, being maintained in
the stem cell state, or differentiating into various cell
types? It will be helpful to assess the in vivo efficiency of
allo-MSCs compared with that of auto-MSCs. Third, the
factors that influence their therapeutic effects and how
they result in the present inconsistent results are far from
clear. Last, strategies to enhance the consistency and effi-
cacy of allo-MSCs as a cell-based therapy should be inves-
tigated in inflammatory diseases as well as for tissue
repair.
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